Actively Recruiting
Registry Study Collecting Patient Outcomes, Quality of Life, and Treatment Data in Idiopathic Pulmonary Fibrosis and Progressive Chronic Fibrosing Interstitial Lung Diseases
Led by Duke University · Updated on 2026-08-12
3000
Participants Needed
47
Research Sites
156 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying Idiopathic Pulmonary Fibrosis IPF and other chronic fibrosing interstitial lung diseases ILDs with a progressive phenotype through the IPF-PRO and ILD-PRO Registries. This prospective registry collects data on the natural history, healthcare experiences, quality of life, and treatments of participants diagnosed with IPF or other chronic fibrosing ILDs. Blood samples and chest imaging studies are also gathered and stored for future research. The registry originally enrolled over 1000 participants with IPF and expanded to include other fibrosing ILDs with progressive phenotypes, aiming to enroll up to 1000 additional patients in each phase.
CONDITIONS
Brief Title
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Research Team
R
Rosalia Blanco
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
